World Wound Care Markets (Skin Ulcer, Burns, Surgical/Trauma)
US$ 3,995.00
... Information report, World Wound Care Markets, is the latest edition of Kalorama's comprehensive look at markets for wound care products in skin ulcer, burn ... , obesity, pulmonary and vascular diseases, immobility issues and chronic wounds. These factors are all influenced by future demographic trends, economic ...
June 2012
240 pages
Medicated Skin Care in Greece
US$ 990.00
There were no significant developments in medicated skin care in Greece during 2011. The lack of innovation resulted in declining value sales ... many, the purchase of many medicated skin care products began is now regarded as unnecessary and in many... Euromonitor International's Medicated Skin Care in Greece report offers a comprehensive guide to the ...
June 2012
35 pages
Medicated Skin Care in Norway
US$ 990.00
... period. Competition from beauty care brands and price competition among retailers dampened growth. Euromonitor International's Medicated Skin Care in Norway report offers a comprehensive guide ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
June 2012
37 pages
Medicated Skin Care in Sweden
US$ 990.00
... skin care products, represented a key challenge to the value growth of medicated skin care in Sweden in 2011. This was due to the increasingly advanced and complex nature of cosmetic skin care offerings which made the differences between cosmetic skin care ...
June 2012
26 pages
Medicated Skin Care in the United Kingdom
US$ 990.00
Sales of medicated skin care declined marginally in 2011, to £285 million. Paediatric medicated skin care and hair loss treatments were the fastest growing categories, as ... the only other categories to see growth of over 2%. Euromonitor International's Medicated Skin Care in United Kingdom report offers a comprehensive guide to the size and shape of the ...
June 2012
41 pages
Medicated Skin Care in India
US$ 990.00
... treatments and medicated shampoo products among lower middle class households is enhancing sales of such products across India. Euromonitor International's Medicated Skin Care in India report offers ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
June 2012
33 pages
Medicated Skin Care in Ireland
US$ 990.00
... enough to compensate for the lost sales earlier... Euromonitor International's Medicated Skin Care in Ireland report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
June 2012
38 pages
Celgene: Long-Term Prospects Intact but Competition Emerging!
US$ 140.00
... flat growth of Revlimid (L, RRMM, MDS), reported in its 1Q12, we expect Celgene (CELG) to meet its FY12 guidance (Total rev.: $5.4-$5.6b and EPS ... , please read our report, released on 12th June on CELG, titled “Long-Term Prospects Intact but Competition Emerging!”
June 2012
3 pages
Sanofi, ORIGIN TRIAL – No Implications, but removes the cancer risk overhang
US$ 90.00
The ORIGIN trial was intended to expand Lantus use in the ... existing use in the late stage setting. In the trial, Lantus did delay the progression of pre-diabetes to diabetes ... disadvantage. The only positive implication for Lantus from the ORIGIN trial is that it completely removes the cancer risk overhang on ...
June 2012
2 pages
The European League Against Rheumatism (EULAR) 2012 Noteworthy Takeaways
US$ 140.00
Among all oral options for the treatment of Rheumatoid Arthritis (RA), JAK inhibitors are ready to reach the market but the debate will continue – whether targeting specific JAK-1, 2, &3 or a multipronged approach like JAK 1/2, 1/3 is better? JAK1 may be the most suitable target as an anti-inflammatory drug ...
June 2012
10 pages
ELAN- A Tale of Two: Tysabri = Support; Bapineuzumab = Upside
US$ 300.00
... REMS program for PML risk have driven and anchored Elan Corp.'s (ELN), but future growth is highly dependant on the success ... , Please read our report released on June 11, 2012 on ELN, titled “A Tale of Two: Tysabri = Support; Bapineuzumab = Upside”.
June 2012
12 pages
VERTEX PHARMA - Time to Book Profits
US$ 140.00
Vertex (VRTX) has evolved from an innovator to a profitable Biotech but at the ... detail, please read our report released on 11th June, 2012 on Vertex titled “Time to Book Profits….!”
June 2012
4 pages
Medicated Skin Care in Costa Rica
US$ 990.00
... , although not at the same pace as in previous years. Euromonitor International's Medicated Skin Care in Costa Rica report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
June 2012
23 pages
Medicated Skin Care in Belgium
US$ 990.00
Many products in medicated skin care are not considered crucial by consumers or face competition from reimbursed Rx products. Thus, sales of medicated skin care were affected directly by the ... and other skin complaints, which began during the first half of the review period, were less effective in... Euromonitor International's Medicated Skin Care in Belgium report ...
June 2012
41 pages
The Market for Mobile Medical Apps
US$ 2,500.00
... ) Medical Reference Clinical Support Systems The total mobile medical app market is also broken out by region including US, Europe, Asia and Rest of World ... has exhibited a particular need for these technologies. Not only is the medical community using smartphones and their applications for basic work at ...
June 2012
109 pages
Novartis, ACZ885 – Impressive data in SJIA, but no meaningful commercial opportunity
US$ 90.00
Novartis today reported positive Phase 3 data on ACZ885 (canakinumab) in SJIA. The data is impressive but commercial opportunity would be limited as SJIA is a rare disease, while ... 20000 or less depending on the weight. While if NVS chose to price ACZ885 at its existing annual cost ($100,000), it may not be able ...
June 2012
1 pages
Life Sciences & Analytical Reagents Market Applications, Current Trends, Opportunities & Global Forecasts (2011 – 2016)
US$ 5,650.00
... ) & ANALYTICAL REAGENTS (Chromatography, Mass Spectrometry, Electrophoresis, Flow Cytometry) MARKET APPLICATIONS (Protein Purification, Gene Expression, DNA & RNA Analysis, & Drug Testing), CURRENT TRENDS, OPPORTUNITIES & GLOBAL FORECASTS (2011 – 2016) Biotechnology (life science and analytical) reagents are ...
June 2012
326 pages
China Healthcare Market Analysis
US$ 700.00
... participation. Although China healthcare market is fraction of the developed markets, it is actually witnessing double digit growth in recent years. However, within the Chinese healthcare market landscape,there ... increasing the healthcare expenditure’s percentage of the GDP. “China Healthcare Market Analysis” research report gives detailed overview on the multiple aspects related to healthcare system in China. It helps to understand ...
June 2012
94 pages
Ear Care in Singapore
US$ 990.00
... low awareness of ear care products, limiting potential demand amongst consumers who choose from what is available. Euromonitor International's Ear Care in Singapore report offers a comprehensive ... books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and ...
May 2012
19 pages
Medicated Skin Care in Singapore
US$ 990.00
... ; the increased participation in sport in Singapore’s humid weather can be said to be a factor in this regard. Euromonitor International's Medicated Skin Care in Singapore report offers a comprehensive guide to the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
25 pages
The Chinese R&D Landscape - Medical Technology
US$ 1,200.00
R&D in China in the field of medical technology* has surged over the last decade. This report seeks to answer the following questions related to this surge in R&D:
Where in China does the...
May 2012
12 pages
Erythropoietin Market Forecast to 2015
US$ 400.00
In the biopharmaceutical industry, protein-based therapies have become one of the most effective clinical methods to treat a wide spectrum of diseases, ranging from cancer to metabolic disorders. Acco...
May 2012
34 pages
Human Growth Hormone Market Forecast to 2015
US$ 400.00
Since the launch of human insulin product, protein-based therapies have found a prominent place in the biopharmaceutical industry. According to our new research report on Human Growth Hormone (HGH) Ma...
May 2012
34 pages
Indian Oral Care Market Forecast to 2015
US$ 250.00
In India, oral care segment holds a substantial share in the overall cosmetic market. On back of increasing awareness about oral hygiene, improving income, and high advertising expenditure by players,...
May 2012
26 pages
Interferon Market Forecast to 2015
US$ 400.00
One of the most effective clinical methods, used to treat a wide spectrum of diseases, protein-based therapies have found a prominent place in the biopharmaceutical industry. According to our new rese...
May 2012
37 pages
SUN PHARMA: Strong Quarter and Brighter Outlook
US$ 140.00
We reiterate Sun Pharma as our Top Pick in the Indian pharma space after its higher ... growth like (1) continuing sales of Doxil generic after Sun gets ANDA approval (2) launch of Prandin, Comtan ... In addition to the near term drivers, we see Sun Pharma positioning itself to become a leader in global generics with ...
May 2012
7 pages
IPCA- Ready to Fire from All Directions
US$ 140.00
IPCA’s Q4 FY12 result was slightly below our ... on Q-o-Q basis mainly due to the reduction in production as IPCA implemented the track and trace system in its manufacturing facility ... margin of 5%) too impacted the business. We remain enthused about Ipca’s 18-20% growth guidance for domestic pharma in FY13. We rate ...
May 2012
7 pages
Medicated Skin Care in Georgia
US$ 990.00
... by stronger advertising for many products, both from OTC medicated skin care and from cosmetic skin care players. In addition, the leading chains in chemists/pharmacies ... , consumers become more confident in their self-medication and buy a wider range of medicated skin care. Euromonitor International's Medicated Skin Care in Georgia report offers a comprehensive guide to the size ...
May 2012
24 pages
Medicated Skin Care in Thailand
US$ 990.00
... consumers walked in water with their common slippers or... Euromonitor International's Medicated Skin Care in Thailand report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
33 pages
Medicated Skin Care in Macedonia
US$ 990.00
... and Kantarion, from Alkaloid and Fitopharm respectively. Euromonitor International's Medicated Skin Care in Macedonia report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
23 pages
Medicated Skin Care in Finland
US$ 990.00
... the gloomier outlook for the Finnish economy. Euromonitor International's Medicated Skin Care in Finland report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
34 pages
Ear Care in Slovakia
US$ 990.00
... years, awareness of ear care consistently increased, as consumers started to pay more attention to and look after their ears properly, as they care for other parts of their body. In 2011, ear care grew by 1% in current value terms. Euromonitor International's Ear Care in Slovakia report offers ...
May 2012
20 pages
Medicated Skin Care in Cameroon
US$ 990.00
... needing medicated skincare or teenagers with acne treatments or other skin treatments. The category experienced 5% current value growth in 2011. Euromonitor International's Medicated Skin Care in Cameroon report ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
19 pages
Medicated Skin Care in Poland
US$ 990.00
... special attention to the health benefits of self-medication and the high efficacy of available... Euromonitor International's Medicated Skin Care in Poland report offers a comprehensive guide to the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
32 pages
Medicated Skin Care in Slovakia
US$ 990.00
... for various skin infections. Slovak consumers are very sensitive about their skin problems and pay more attention to prevention. Therefore, medicated skin care is becoming more popular each year. In 2011, it grew by 2% with overall current value sales reaching EUR13.3 million. Euromonitor International's Medicated Skin Care in Slovakia report ...
May 2012
27 pages
The Art of Positioning Dietary Supplements
US$ 2,000.00
... regulatory activity. An effective message regarding health benefits, and the localisation of products will advance sales. Euromonitor International’s The Art of Positioning Dietary Supplements global briefing examines the size, growth trends and potential opportunities in the Consumer Health market. The ...
May 2012
60 pages
Medicated Skin Care in Spain
US$ 990.00
... economic conditions experienced in Spain are clearly affecting sales of medicated skin care as they did the rest of Spanish consumer health. Moreover in Spain, in 2011 the number ... of unemployment distress in Spain, as although one member may be unemployed the economic needs of the family unit... Euromonitor International's Medicated Skin Care in Spain report offers a comprehensive ...
May 2012
38 pages
Merck KGaA in Consumer Health (World)
US$ 572.00
Merck KGaA is a global top 20 producer of consumer health products. Despite relatively consistent revenue growth, the company has struggled to consistently gain share of the global consumer health ... . Euromonitor International’s Merck KGaA in Consumer Health (World) Company Profile offers detailed strategic analysis of the company’s business, examining its performance in the Consumer Health industry. The ...
May 2012
34 pages
Medicated Skin Care in Colombia
US$ 990.00
... . Haemorrhoid treatments increased by 7% in current value terms in 2011. Euromonitor International's Medicated Skin Care in Colombia report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
35 pages
Medicated Skin Care in Brazil
US$ 990.00
... experienced during the review period can largely be... Euromonitor International's Medicated Skin Care in Brazil report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
46 pages
Medicated Skin Care in Bosnia-Herzegovina
US$ 990.00
... as a whole, medicated skin care’s performance in 2011 was quite similar at 5% in current value terms. Medicated skin care recovered in 2011 from a decline in 2010 caused by the recession. Skin care problems ... , which means that demand for medicated skin care products is quite elastic during periods of economic instability. Euromonitor International's Medicated Skin Care in Bosnia-Herzegovina report offers a comprehensive guide ...
May 2012
22 pages
CIPLA - Nothing New – As Expected
US$ 140.00
... ‘rationalization’ of various partnerships in different geographies. Launch of Dymista and Vancomycin by Cipla’s partners in US too may not fetch any meaningful upside in the ... near term. We reiterate our Market Perform on Cipla but change our target price to `341 as we rollover to FY13 ...
May 2012
7 pages
